Tirzix 2.5 mg

Generic Name: Tirzepatide
Brand Name: Tirzix
Strength: 2.5 mg
Manufacturer: Beacon Pharmaceuticals Ltd.
Form: Prefilled Injection Pen

Description:

Tirzix 2.5 mg is a cutting-edge weekly injectable medication containing Tirzepatide, a dual GIP and GLP-1 receptor agonist. It is primarily indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults, as an adjunct to diet and exercise. Tirzix is also gaining attention for its significant role in weight management in overweight or obese patients with or without diabetes.

Indications:

• Type 2 Diabetes Mellitus: To improve glycemic control in adults

• Weight Management (off-label use): For obesity or overweight patients with comorbid conditions

Pharmacology:

Tirzepatide acts on both Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptors. This dual action enhances insulin secretion, reduces glucagon levels, slows gastric emptying, and decreases appetite — leading to better glycemic control and effective weight loss.

Dosage & Administration:

• Initiate with 2.5 mg once weekly for 4 weeks

• Dose may be escalated based on tolerability and clinical response

• Administered subcutaneously in the abdomen, thigh, or upper arm

Side Effects:

• Common: Nausea, vomiting, diarrhea, constipation, decreased appetite

• Serious (Rare): Pancreatitis, thyroid tumors, hypoglycemia (especially with insulin or sulfonylureas)

Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Hypersensitivity to Tirzepatide

Precautions & Warnings:

• Monitor for thyroid nodules and pancreatitis symptoms

• Caution in patients with renal impairment

• Not recommended during pregnancy or lactation unless necessary

Storage Conditions:

• Store in a refrigerator between 2°C to 8°C

• Do not freeze

• Protect from light

Therapeutic Class:

Incretin-Based Therapies (GIP/GLP-1 Receptor Agonist)